Meeting
2023 ASCO Annual Meeting
Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.
Authors
Joshua E. Reuss
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
Joshua E. Reuss , Nishant Gandhi , Phillip Walker , Jorge J. Nieva , Jean Gabriel Bustamante Alvarez , Jennifer W Carlisle , Aakash Desai , Ari M. Vanderwalde , Patrick C. Ma , Stephen V. Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9069)
DOI
10.1200/JCO.2023.41.16_suppl.9069
Abstract #
9069
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
First Author: Samuel Rosner
Poster
2021 ASCO Annual Meeting
Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.
First Author: Yufei Liu
Poster
2019 Breakthrough
Mutation spectrum of major cancer driver genes in Vietnamese NSCLC patients.
First Author: Uyen Vu Tran
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna